July 6, 2020
Heta compiler has been published on GitHub as an OpenSource
(Moscow-06.07.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents Heta compiler which is a tool for the development of Quantitative Systems Pharmacology and Systems Biology platforms. Particularly, it allows combining modules written in different formats like: Heta language code, Excel sheets, JSON, YAML formatted structures, SBML and transforming them into the dynamic models of different formats.
It should be outlined, that Quantitative Systems Pharmacology (QSP) is a discipline that uses mathematical computer models to characterize biological systems, to determine the optimal doses, target groups of patients and substances effect on the human body. QSP typically functions through mechanism-based dynamical models described by ODE systems. Therefore, the modeling systems may include hundreds or thousands of components and are developed by a research group involving people with different expertise. Evgeny Metelkin, Head of InSysBio product development, highlights: “Heta compiler can be used as the framework for a QSP modeling project of any size and complexity. It can be easily integrated with existed infrastructure, workflows or used as a part of the CI/CD strategy”.
Actually, Heta compiler is a tool that allows to perform a number of functions, namely:
Heta compiler is developed as Free Open Source project published on GitHub. The actual version of Heta compiler is 0.5.3, which supports Heta language of version 0.3.1.
Heta compiler is written in JаvaScript/Node language and is distributed as a npm package. This software can work in command line tool mode or may be used as a package for browser or server-side tools and applications.
Heta compiler has already supported the fulfillment of a number of InSysBio projects, namely:
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | November 2018 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
| |||
|
5
|
6
1.
06 Nov 2018 17:27
Investigation of amyloid pathology mechanisms and prediction of clinical trial results using QSP model
InSysBio presents the video of Tatiana Karelina’s talk in framework of session “From translational PKPD models to quantitative system pharmacology in neurodegeneration drug development” at the 9th American Conference on Pharmacometrics (ACoP9):
|
7
|
8
|
9
|
10
|
11
|
|
12
|
13
|
14
|
15
|
16
|
17
|
18
|
|
19
|
20
|
21
|
22
|
23
|
24
|
25
|
|
26
1.
26 Nov 2018 14:03
InSysBio updates Immune Response Template online
InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, today announced a release of updated version of Immune Response Template (IRT) online. The main update in new 2.1.0 version is myeloid-derived suppressor cells (MDSCs). Published human in vitro and in vivo data were analyzed to reconstruct monocytic MDSCs (Mo-MDSCs) and granulocytic MDSCs (Gr-MDSCs) life cycles, derive equations and identify parameters.
|
27
|
28
|
29
|
30
| ||